Today: 29 April 2026
Browse Category

TSX:4523 30 August 2025 - 12 January 2026

Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio shares fell 17.7% to $6.62 Monday after announcing a licensing deal with Eisai and releasing initial sales data for its lung-cancer drug. Eisai will pay €50 million upfront for rights outside the U.S., China, and Japan, with further milestone payments possible. Fourth-quarter Ibtrozi sales met estimates, but investors appeared cautious on future prescription growth.
12 January 2026
····
Japan Stock Market Today: Nikkei 225 Ends Flat as SoftBank Crashes on AI Jitters – November 25, 2025

Japan Stock Market Today: Nikkei 225 Ends Flat as SoftBank Crashes on AI Jitters – November 25, 2025

SoftBank Group shares plunged 9.95% in Tokyo on Tuesday, erasing most of the Nikkei 225’s early gains and wiping an estimated 338 points from the index. The Nikkei closed up just 0.07% at 48,659.52 after surging more than 1% at the open, while the Topix slipped 0.21%. Turnover on the Topix was above the three-month average.
25 November 2025
·········
Science Shockers: AI-Created Viruses, “Water Worlds” Debunked & More (Sept 19–20, 2025)

Science Shockers: AI-Created Viruses, “Water Worlds” Debunked & More (Sept 19–20, 2025)

Researchers used AI to design the first viruses from scratch, creating bacteriophages that killed drug-resistant bacteria. Scientists solved why smoking affects ulcerative colitis and Crohn’s disease differently, linking it to mouth bacteria. New Alzheimer’s drugs modestly slowed disease in early stages. Wildfire smoke could kill 70,000 Americans annually by 2050, Stanford researchers warned.
20 September 2025
·····
Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

The FDA approved Leqembi IQLIK, the first at-home injectable Alzheimer’s treatment, enabling weekly self-administered doses. U.S. regulators also cleared Sanofi’s Wayrilz, the first BTK inhibitor for chronic immune thrombocytopenia. Cytokinetics’ aficamten outperformed metoprolol in a Phase 3 heart drug trial. WHO warned Gaza has run out of critical medical supplies amid a spike in Guillain-Barré syndrome cases.
30 August 2025
····

Stock Market Today

  • Chevron (CVX) Appears Undervalued After 10.8% Drop: DCF Analysis Shows 47.5% Discount
    April 28, 2026, 10:57 PM EDT. Chevron's shares closed at $188.36, down 10.8% over the past month but up 41.3% over the last year. A Discounted Cash Flow (DCF) analysis estimates Chevron's intrinsic value at $358.56 per share, suggesting the stock trades at a 47.5% discount, indicating potential undervaluation. The DCF model factors in free cash flow projections through 2035, reflecting a strong future cash generation outlook. Chevron's price-to-earnings (P/E) ratio stands at 30.5x, elevated relative to the Oil and Gas sector average, reflecting market expectations for earnings growth and risk. Investors continue to weigh commodity prices, capital spending, and shareholder return policies amid fluctuating energy market conditions.

Latest article

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

29 April 2026
Oracle shares fell 4% and CoreWeave dropped 5.9% Tuesday after a Wall Street Journal report said OpenAI missed recent revenue and user targets. Nvidia, AMD, and Arm Holdings also declined, with the iShares Semiconductor ETF down 3.7%. OpenAI denied internal divisions and said its AI coding product Codex reached 4 million users. Oracle’s credit default swaps hit a two-week high amid concern over its $300 billion cloud deal with OpenAI.
Go toTop